Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.53−0.23 (-2.68%)
Close on Nov 13, 2026Market cap $1.41BP/E –Yield –
Novavax ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Novavax's ebitda for the twelve months ending Sep 30, 2026 was -$72.71M, down 121.3% year over year. For fiscal 2025 it was $480.80M. The highest annual figure on record is $480.80M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.80M | – |
| FY2024 | Dec 31, 2024 | -$200.93M | – |
| FY2023 | Dec 31, 2023 | -$525.51M | – |
| FY2022 | Dec 31, 2022 | -$615.74M | – |
| FY2021 | Dec 31, 2021 | -$1.67B | – |
| FY2020 | Dec 31, 2020 | -$412.42M | – |
| FY2019 | Dec 31, 2019 | -$115.48M | – |
| FY2018 | Dec 31, 2018 | -$166.52M | – |
| FY2017 | Dec 31, 2017 | -$164.11M | – |
| FY2016 | Dec 31, 2016 | -$261.41M | – |
| FY2015 | Dec 31, 2015 | -$152.14M | – |
| FY2014 | Dec 31, 2014 | -$79.29M | – |
| FY2013 | Dec 31, 2013 | -$49.83M | – |
| FY2012 | Dec 31, 2012 | -$27.97M | – |
| FY2011 | Dec 31, 2011 | -$19.98M | – |
| FY2010 | Dec 31, 2010 | -$37.09M | – |
| FY2009 | Dec 31, 2009 | -$36.19M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$28.23M | – |
| Q2 FY2026 | Jun 30, 2026 | -$51.85M | -147.7% |
| Q1 FY2026 | Mar 31, 2026 | -$12.37M | -102.4% |
| Q4 FY2025 | Dec 31, 2025 | $19.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$171.43M | – |
| Q2 FY2025 | Jun 30, 2025 | $108.63M | -36.9% |
| Q1 FY2025 | Mar 31, 2025 | $523.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$119.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$121.32M | – |
| Q2 FY2024 | Jun 30, 2024 | $172.13M | +162.7% |
| Q1 FY2024 | Mar 31, 2024 | -$132.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$173.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$114.31M | – |
| Q2 FY2023 | Jun 30, 2023 | $65.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$303.73M | -240.6% |
| Q4 FY2022 | Dec 31, 2022 | -$236.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$118.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$476.24M | – |
| Q1 FY2022 | Mar 31, 2022 | $216.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$820.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$302.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$343.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$206.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.05M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$34.74M | – |
| Q1 FY2019 | Mar 31, 2019 | -$38.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$45.29M | – |
| Q3 FY2018 | Sep 30, 2018 | -$39.86M | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.94M | – |
| Q1 FY2018 | Mar 31, 2018 | -$41.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$47.88M | – |
| Q3 FY2017 | Sep 30, 2017 | -$38.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$39.42M | – |
| Q1 FY2017 | Mar 31, 2017 | -$38.72M | – |
| Q4 FY2016 | Dec 31, 2016 | -$52.63M | – |
See a number that looks wrong?